deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT02919644

Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. (COREVAX-1)

Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer: a Phase II Study

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Updated 11 times since 2017 Last updated: Sep 17, 2024 Started: Dec 2, 2016 Primary completion: Dec 31, 2026 Completion: Dec 31, 2031
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02919644, this PHASE2 trial focuses on Curative Resection and Stage IV Colorectal Cancer and remains actively recruiting participants. Sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, it has been updated 11 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshotActive Not Recruiting~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshotActive Not Recruiting~Dec 2018 – ~May 2020 · 17 months · monthly snapshotActive Not Recruiting~May 2020 – ~Jan 2021 · 8 months · monthly snapshotRecruiting~Jan 2021 – ~May 2024 · 40 months · monthly snapshotRecruiting~May 2024 – ~Jul 2024 · 2 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshotUnknown~Oct 2024 – ~Apr 2025 · 6 months · monthly snapshotRecruiting~Apr 2025 – present · 15 months · monthly snapshotRecruiting

Change History

11 versions recorded
  1. Apr 2025 — Present [monthly]

    Recruiting PHASE2

  2. Oct 2024 — Apr 2025 [monthly]

    Recruiting PHASE2

    Status: UnknownRecruiting

  3. Sep 2024 — Oct 2024 [monthly]

    Unknown PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown StatusUnknown

  5. May 2024 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: RecruitingUnknown Status

Show 6 earlier versions
  1. Jan 2021 — May 2024 [monthly]

    Recruiting PHASE2

  2. May 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Active Not RecruitingRecruiting

  3. Dec 2018 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Data source: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations